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Aims: Cancer cells induce de novo lymphatic vessel growth within draining lymph 
nodes before they metastasize. Lymph node lymphangiogenesis before the 
establishment of nodal recurrence in squamous cell carcinoma (SCC) of the tongue was 
evaluated retrospectively. 
Methods and Results: Surgical specimens from 28 patients with pT2-T3N0M0 SCC of 
the tongue after local excision with supraomohyoid neck dissection were studied by 
immunohistochemistry. Intranodal lymphatic endothelium was highlighted by 
podoplanin staining to evaluate the lymphatic vessel counts (LVC). Primary tumor 
sections were examined for the expressions of lymphangiogenic factors: vascular 
endothelial growth factor (VEGF)-C and VEGF-D. LVC in the regional LN was 
significantly increased in the cases with nodal recurrence (p=0.0013). Simultaneous 
increases of VEGF-C and VEGF-D protein expressions were also significantly 
associated with an increase of LVC in regional lymph nodes (p=0.0001) and a decrease 
in the survival rate without nodal recurrence (p=0.0160).  




tongue cancer would help us predict patients developing nodal recurrence. The 
inclusion of a therapeutic approach to block lymphangiogenic factors, such as VEGF-C 
and VEGF-D, may be beneficial to suppress the lymphatic spread of tongue cancer with 
intense intranodal lymphangiogenesis. 
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The lymph node metastatic status is a predictor of a poor prognosis in patients 
with tongue cancer. Moreover, patients who experience neck recurrence after initial 
treatment frequently die of uncontrolled neck diseases 1, 2, and many candidates for 
prediction have been evaluated 3, 4. More than 30% of patients with tongue cancer have 
cervical lymph node metastases, even in clinically node-negative disease 5. Among 
patients with clinically T1/T2 or N0 tongue cancer, the regional recurrence rate of the 
untreated neck is 20 to 30% 6, 7. However, the treatment planning for regional control of 
clinically node-negative squamous cell carcinoma (SCC) of the tongue is controversial. 
Some surgeons advocate elective neck dissection, while others adopt a 
“watchful-waiting” policy after local excision. Recently, sentinel node navigation 
surgery has been introduced for the detection of micrometastasis in lymph nodes 1, 2. 
However, the accuracy of the prediction is not perfect, and the predictive values of 
negative sentinel lymph nodes are about 90% 8. Therefore, it is vital to identify 
prognostic parameters that influence the occurrence of nodal recurrence. 




pre-existing ones with the aid of circulating lymphatic endothelial progenitor cells, is 
believed to underlie lymph node metastases 9. Owing to the advent of molecular 
markers specific to the lymphatic endothelium, including lymphatic vessel endothelial 
hyaluronan receptor 1, podoplanin, and prospero homeobox protein 1, research on 
tumor lymphangiogenesis has been conducted over the last decade. Some clinical 
studies reported that the lymphatic vessel density in many types of solid cancer were 
associated with the status of lymph node metastases at the initial diagnosis 10-13. 
Moreover, experimental studies have indicated that primary tumors induce new 
lymphatic vessel growth within draining lymph nodes before they metastasize 11, 14, 15.  
 Vascular endothelial growth factor (VEGF)-C and VEGF-D, members of the 
VEGF family of glycoproteins, have been identified as potent inducers of 
lymphangiogenesis 9. VEGF-C and VEGF-D exert their effects on endothelial cells by 
stimulating VEGF receptor 3 (VEGFR-3), a tyrosine kinase receptor expressed 
predominantly on lymphatic endothelial cells 16. Overexpressions of VEGF-C and 
VEGF-D in experimental tumor models were significantly associated with the 




of VEGF-C and VEGF-D activities reduced the level of lymphangiogenesis and lymph 
node metastases 19, 20. In clinical studies, contributions of VEGF-C, VEGF-D, and 
VEGFR-3 to lymph node metastases, lymphatic invasion, and a poor prognosis have 
been observed in several malignancies 21-23. 
This study was performed to evaluate the role of lymphangiogenesis in regional 
lymph nodes as a predictor of nodal recurrence in patients with pT2-T3N0 SCC of the 
tongue treated primarily by local excision with supraomohyoid neck dissection. In 
addition, the relationships between lymph node lymphangiogenesis and nodal 
recurrence in association with the expressions of VEGF-C and VEGF-D proteins were 
analyzed.  




Materials and Methods  
Patients and tissues (Table 1) 
The samples studied were obtained from 28 patients who were diagnosed with 
pT2-T3N0M0 SCC of the tongue based on the TNM classification system of the Union 
Internationale Contre le Cancer after local excision and supraomohyoid neck dissection 
24. To correctly analyze the association of intranodal lymphangiogenesis with nodal 
recurrence, patients who experienced local relapse were not included in this study. 
Cases classified as pT4 were also excluded from the analyses. All patients were treated 
at the Division of Otolaryngology, Head and Neck surgery, Kanazawa University 
Hospital, between 1982 and 2006. The Institutional and Ethical Review Board at 
Kanazawa University approved this retrospective review of the medical records and the 
use of archived surgical specimens. 
Twenty cases were stage II (pT2N0M0) and eight cases were stage III 
(pT3N0M0). The patients comprised 17 males and 11 females, and the ages ranged from 
25 to 86 years old (median, 61 years old). All surviving patients had undergone a 




at 14, 6, 32, 48, 7, and 9 months and recurrence sites were contralateral level I, and 
ipsilateral levels V, IV, II, III, and IV (patient numbers 1-6, Table 1), respectively. 
     The depth of invasion was measured from the surface of the mucosa to the 
maximum depth using an ocular micrometer. When there was exophytic tumor growth, 
the measurement was made from the height of the surface of the adjacent normal 
mucosa to the deepest-reaching front of the infiltration. The data on the depth of 
invasion and lymphatic invasion are also shown in Table 1. 
 
Immunohistochemical analyses 
The surgical specimens including the primary tumors and regional lymph nodes 
were fixed in a 10% formalin solution and embedded in paraffin. Consecutive 3-μm 
sections were cut from each block. Immunohistochemical stainings were performed as 
described previously 25. The following antibodies were used as primary antibodies: 
mouse-derived monoclonal antibody for podoplanin（Dako, CA, USA）(dilution 1:100), 
rabbit-derived polyclonal antibody for VEGF-C (Invitrogen, CA, USA) (dilution 1:100), 




1:50), and mouse-derived monoclonal antibody for pan-cytokeratin (Dako, CA, USA) 
(dilution 1:100). Diaminobenzidine tetrahydrochloride was used as a chromogen, and 
the sections were counterstained with methyl green. The specificities of the staining 
were confirmed using non-immune serum instead of the primary antibody as a negative 
control. Two investigators (K.H. and N.W.) who had no prior knowledge of the 
clinicopathological findings assessed the lymphatic vessel counts (LVC) and 
expressions of VEGF-C and VEGF-D proteins. Each lymph node was analyzed for 
pan-cytokeratin to detect metastatic tumor cells, and patients with positive staining were 
not included in this study. 
 
Evaluation of LVC in pN0 regional lymph nodes 
To evaluate the level of lymhangiogenesis in lymph nodes, the antibody for 
podoplanin was used to identify the lymphatic endothelium. Lymphatic vessels were 
assessed under light microscopic examination of the podoplanin-positive microvessels 
in the biggest lymph node of the surgical specimen. The whole lymph node section was 




spots) were determined. After four areas with intense lymphangiogenesis were 
identified, lymphatic vessels were counted in a ×200 field, and the average count per 
field (1.1 mm2) of the four fields was defined as LVC. Any brownish-staining 
endothelial cell or endothelial-cell cluster was considered a single countable lymphatic 
vessel. 
 
VEGF-C and VEGF-D expressions 
Primary tumor sections were examined for VEGF-C and VEGF-D protein 
expressions. Staining results for VEGF-C and VEGF-D in the primary tumors were 
classified by estimating the percentage of tumor cells showing specific 
immunoreactivity. Negative staining was defined when the degree of staining was < 
25%, and the staining was defined as positive when the degree of staining was ≧ 25%. 
The threshold of 25% of cells expressing VEGFs was selected according to the median 
value of each expression. 
For further analyses, all cases were then divided into the following two groups 




(VEGF-C&D): High group, both VEGF-C and VEGF-D were positive; and Low group, 




IBM SPSS Statistics, version 19 (IBM, Armonk, USA), was used for data 
analyses. The development of nodal recurrence and expressions of VEGF-C and 
VEGF-D proteins in relation to LVC were analyzed using the Mann-Whitney U test. 
The rates of survival without nodal recurrence were analyzed with the Kaplan-Meier 
method, and the differences between the curves were analyzed with the log-rank test. 
The survival period was defined as the period between the date of surgery to that of 
nodal recurrence. For statistical analyses, the depth of invasion was subdivided into two 






Detection of lymphatic vessels in pN0 regional lymph nodes (Figure 1A, Table 1) 
Immunohistochemical staining showed that antibody specific for podoplanin 
reacted with the endothelial cells of lymphatic vessels in pN0 regional lymph nodes, as 
expected according to its established role as a lymphatic marker. Most lymphatic vessels 
highlighted by podoplanin staining were detected as scattered in the stroma of the 
lymphatic tissues. LVC of each case is shown in Table 1. The median LVC in the 
current cohort of patients was 12, with a range from 0 to 55. 
 
VEGF-C and VEGF-D protein expressions at the primary sites (Figure 1B and 1C, 
Table 1)  
VEGF-C and VEGF-D proteins were observed in the cytoplasm of tumor cells. 
According to the criteria for immunohistochemical staining of these proteins, VEGF-C 
and VEGF-D expressions were evaluated as positive in 18 and 14 out of 28 patients, 
respectively. Eleven out of the 28 patients belonged to the High group regarding 





LVC in regional lymph nodes was associated with nodal recurrence, and VEGF-C 
and VEGF-D protein expressions in the primary tumor (Table 2)  
A significant correlation was identified between the increasing number of LVC in 
the regional lymph nodes and development of nodal recurrence during the follow-up 
period (p = 0.0013). Although the patients who were VEGF-C-positive had a greater 
LVC value in the regional lymph nodes compared with their negative counterparts, the 
difference was not significant (p = 0.1480). On the other hand, VEGF-D-positive cases 
had a significantly higher LVC in the regional lymph nodes than VEGF-D-negative 
cases (p=0.0012). When the evaluations of each protein were combined (VEGF-C & D), 
the High group displayed significantly higher LVC values compared with the Low 
group (p = 0.0001). Thus, simultaneous increases of VEGF-C and VEGF-D were 
strongly associated with increasing lymphangiogenesis in the regional lymph nodes. 
 
VEGF-C&D expression was associated with nodal recurrence (Figure 2) 




and VEGF-D (VEGF-C&D) expressions in the primary tumor, and the rates of survival 
without nodal recurrence were examined. The rates of survival without nodal recurrence 
were associated with neither VEGF-C nor VEGF-D expression (Figure 2A and 2B). 
However, in the combined analyses, the High group had a significantly lower survival 
rate without nodal recurrence compared with the Low group (p = 0.0160) (Figure 2C).  
The relationship between the depth of invasion and lymphatic invasion, and 
survival rates without nodal recurrence were also examined. The rates of survival 
without nodal recurrence were associated with neither the depth of invasion nor 





In the present study, LVC in regional lymph nodes was associated with nodal 
recurrence , and could be a significant prognostic parameter in patients with pN0 tongue 
carcinoma. Even in pN0 lymph nodes, lymphatic vessels were increasing in number to 
prepare for the subsequent lymphatic spread. The high-level expressions of VEGF-C 
and VEGF-D proteins had a significant impact on increasing regional lymph node LVC 
and the development of nodal recurrence. That is, lymphangiogenic factors such as 
VEGF-C and VEGF-D secreted by tumor cells would facilitate lymphangiogenesis in 
regional lymph nodes, which increases the possibility of nodal recurrence. This result is 
in line with earlier animal studies on lymph node lymphangiogenesis which focused on 
its role in the premetastatic remodeling of lymphatic vessels at sentinel lymph nodes 14, 
26.  
Our study demonstrated that VEGF-C alone was less associated with lymph node 
LVC compared to VEGF-D. The data are not compatible with reports which suggested a 
significant correlation between VEGF-C expression and LVC 12, 17, 26. The most likely 




patients in other studies were pN+ 12, 17, 26. As is reported in the study of Hirakawa et al., 
VEGF-D is a potent inducer of lymph node lymphangiogenesis in the early phase, 
whereas VEGF-C would have more of an effect on lymph node lymphangiogenesis in 
the late phase of lymph node metastases 26. Combination analysis of VEGF-C&D 
expression showed that tumors of the High group had a higher number of LVC and 
higher incidence of nodal recurrence compared with the Low group. Thus, when the 
tumor cells are positive for both VEGF-C and VEGF-D proteins, these factors would 
work additively to facilitate lymphangiogenesis, which results in a more agressive 
lymphatic spread of the tumor cells at both phases of lymph node metastases. 
Recent studies on different types of cancer have highlighted the importance of 
lymph node lymphangiogenesis as a potential prognostic parameter 10-13. Higher levels 
of lymph node lymphangiogenesis are significantly associated with lymph node 
metastases and poor outcomes. In rectal cancer, it was reported that intranodal 
lymphangiogenesis affected the decrease in disease-free survival 27. In a B16 melanoma 
mouse model, it was demonstrated that lymph node lymphangiogenesis in response to 




lymph node lympangiogenesis in the metastatic spread of breast cancer to non-sentinel 
lymph nodes has been shown in human patients 28. These associations of regional or 
sentinel lymph node lymphangiogenesis with a poorer prognosis further suggest that the 
routine detection of lymph node lymphangiogenesis would be a useful method to 
predict the lymphatic spread of cancer cells. 
In conclusion, our strategies to detect lymphangiogenesis in regional pN0 lymph 
nodes in tongue cancer would help us predict patients developing nodal recurrence. In a 
future study, it will be meaningful to evaluate the level of intranodal lymphangiogenesis 
at the metastases-free sentinel lymph node in association with the prediction of nodal 
recurrence in SCC of the tongue. Finally, the inclusion of a therapeutic approach to 
block lymphangiogenic factors, such as VEGF-C and VEGF-D, may be beneficial to 
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Figure 1. Immunohistochemical detections of podoplanin (Original magnification, 
200x) (A), VEGF-C (Original magnification, 100x) (B), and VEGF-D (Original 
magnification, 100x). (A) Podoplanin expression was essentially restricted to vessel 
structures. Lymphatic vessels highlighted by podoplanin staining were detected as 
scattered in the stroma of the lymphatic tissue. (B, C) VEGF-C and VEGF-D proteins 
were localized in the tumor cytoplasms. 
 
Figure 2. Kaplan-Meier estimates of the survival rate without nodal recurrence. The 
differences between the curves were analyzed with the log-rank test. The survival rate 
without nodal recurrence in relation to VEGF-C expression (A), VEGF-D expression 
(B), combination of VEGF-C and VEGF-D expressions (VDGF-C&D) (C), the depth of 
invasion (D), and lymphatic invasion (E).  
